Sep 29, 2023 7:30 am EDT Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
Aug 07, 2023 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Aug 02, 2023 4:01 pm EDT Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
Jul 24, 2023 8:30 am EDT Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
Jul 13, 2023 8:30 am EDT Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
Jun 30, 2023 9:25 am EDT Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Jun 13, 2023 9:15 am EDT Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Jun 07, 2023 9:15 am EDT Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy